Loading...
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
AIM: The aim of this study was to compare the efficacy and safety of once-daily human glucagon-like peptide-1 analogue liraglutide with dipeptidyl peptidase-4 inhibitor sitagliptin, each added to metformin, over 52 weeks in individuals with type 2 diabetes. METHODS: In an open-label, parallel-group...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Blackwell Publishing Ltd
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3085127/ https://ncbi.nlm.nih.gov/pubmed/21355967 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1742-1241.2011.02656.x |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|